Rheumatology.net

Rheumatology Xagena

The 18-month efficacy of a single course of Rituximab ( MabThera, Rituxan ) as compared with conventional immunosuppression with Cyclophosphamide followed by Azathioprine in patients with severe ( org ...


Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody Ustekin ...


The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs ( NSAIDs ), including selective COX-2 inhibitors ( coxibs ) and traditional non-steroidal anti-inflammatory drugs ( t ...


Orencia ( Abatacept ) SC ( subcutaneous ) and IV ( intravenous ) is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and im ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product RoActemra ( To ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product MabThera ( Rit ...


Eli Lilly has announced that it will discontinue the phase 3 rheumatoid arthritis ( RA ) program for Tabalumab, an anti-BAFF ( B cell activating factor ) monoclonal antibody, due to lack of efficacy. ...


the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Cimzia ( Certo ...


Dipeptidyl peptidase-4 inhibitors ( DPP4i ), such as Linagliptin, Saxagliptin, and Sitagliptin, are oral glucose-lowering drugs for type 2 diabetes mellitus ( T2DM ). DPP4 is a transmembrane glycoprot ...


Celgene has announced results of phase II trial ( BCT-001 ) on Apremilast, a oral targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with Behçet’s disease.These data have showed that sign ...


Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in systemic or biologic DMARD-naïve psoriatic arthritis patients.PAL ...


Eli Lilly and Incyte have announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of Baricitinib in patients with active rheumatoid arthritis. Ba ...


A team of researchers has analysed the association between alcohol intake and incidence of rheumatoid arthritis in women. The prospective study has used data from The Swedish Mammography Cohort, a ...


Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional tr ...


Pain management is a high priority for patients with rheumatoid arthritis. Despite deficiencies in research data, neuromodulators have gained widespread clinical acceptance as adjuvants in the managem ...